Subject(s)
Afferent Loop Syndrome , Anastomosis, Surgical , Drainage , Pancreaticoduodenectomy , Humans , Pancreaticoduodenectomy/adverse effects , Pancreaticoduodenectomy/methods , Drainage/methods , Constriction, Pathologic/etiology , Constriction, Pathologic/surgery , Anastomosis, Surgical/adverse effects , Afferent Loop Syndrome/etiology , Afferent Loop Syndrome/surgery , Male , Aged , Middle Aged , Postoperative Complications/surgery , Postoperative Complications/etiologySubject(s)
Afferent Loop Syndrome , Cholangitis , Endosonography , Self Expandable Metallic Stents , Ultrasonography, Interventional , Humans , Afferent Loop Syndrome/etiology , Afferent Loop Syndrome/surgery , Afferent Loop Syndrome/therapy , Cholangitis/etiology , Cholangitis/surgery , Endosonography/methodsABSTRACT
BACKGROUND/PURPOSE: Afferent loop syndrome (ALS) is a rare adverse event after gastrointestinal surgery requiring appropriate early decompression treatment. Several endoscopic interventions have been attempted for treatment, including endoscopic enteral metal stent placement (EMSP), endoscopic ultrasound (EUS)-guided entero-enterostomy (EUS-EE), and EUS-guided hepaticogastrostomy (EUS-HGS). However, there are limited data on outcomes, including duration of stent patency. In this study, we evaluated the usefulness of each endoscopic intervention for malignant ALS. METHODS: We retrospectively investigated nine patients with malignant ALS who underwent EMSP, EUS-EE, or EUS-HGS. Information on technical success, clinical efficacy, adverse events, stent dysfunction, and overall survival was collected and analyzed. RESULTS: The most common symptoms were abdominal pain and cholangitis. ALS was treated by EMSP in three patients, EUS-EE in three patients, and EUS-HGS in three patients. Stent placement was successful and clinically effective in all patients with no adverse events. During follow-up, stent dysfunction occurred in two patients treated by EUS-HGS. Eight patients died of primary disease during a median follow-up of 157 days. CONCLUSIONS: Each of the available endoscopic interventions for malignant ALS can be expected to produce similar outcomes, including duration of stent patency. The choice of endoscopic intervention should be made based on the characteristics of each treatment.
Subject(s)
Afferent Loop Syndrome , Cholestasis , Humans , Afferent Loop Syndrome/diagnostic imaging , Afferent Loop Syndrome/etiology , Afferent Loop Syndrome/surgery , Cholestasis/etiology , Drainage , Endoscopy , Endosonography , Liver/pathology , Retrospective Studies , Stents/adverse effects , Treatment OutcomeABSTRACT
OBJECTIVES: Both clinical experience and supporting data have improved drastically in the context of endoscopic ultrasound-guided gastrointestinal anastomosis (EUS-GIA). Where outcomes used to be questioned, focus has now moved towards performing comparative studies, optimizing technical approaches, improving patient selection, and developing well-defined treatment algorithms. METHODS: The purpose of this review is to provide an overview of technical developments within EUS-GIA and to discuss the current status of EUS-GIA and future directions. RESULTS: EUS-GIA techniques such as EUS-guided gastroenterostomy (EUS-GE), EUS-directed transgastric endoscopic retrograde cholangiopancreatography (ERCP) (EDGE) and EUS-guided treatment afferent loop syndrome have undergone further development, refining technical approaches, improving patient selection and subsequent outcomes. Retrospective evaluations of EUS-GE have shown similar safety when compared to enteral stenting, whilst attaining surgical range efficacy. Whereas, in patients with gastric bypass anatomy, EDGE seems less cumbersome and time consuming than enteroscopy-assisted ERCP, while preventing surgical morbidity associated with laparoscopy-assisted ERCP. Although less evidence is available on EUS-guided treatment of afferent loop syndrome, this technique has been associated with higher clinical success and fewer reinterventions and adverse events when compared to enteral stenting and percutaneous drainage, respectively. Several randomized studies are currently underway evaluating EUS-GE in malignant gastric outlet obstruction (GOO), whereas more prospective data are still required on EDGE and long-term fistula management. CONCLUSION: EUS-GIA has become a crucial alternative to established techniques, overcoming technical limitations and subsequently improving patient outcomes. Although we should focus on prospective confirmation of these results in the context of GOO and EDGE, the current evidence already allows for a prominent role for EUS-GIA in our everyday practice.
Subject(s)
Afferent Loop Syndrome , Gastric Outlet Obstruction , Humans , Afferent Loop Syndrome/etiology , Retrospective Studies , Prospective Studies , Gastroenterostomy/methods , Cholangiopancreatography, Endoscopic Retrograde/methods , Endosonography/methods , Gastric Outlet Obstruction/surgery , Ultrasonography, Interventional/methods , StentsABSTRACT
Afferent loop syndrome (ALS) is a morbid complication that may occur after gastrectomy and gastrojejunostomy reconstruction. The aim of this article is to review the different endoscopic treatment options of ALS. We describe the evolution of the endoscopic treatment of ALS and its limitations despite the overall propitious profile. We analyze the advantages of endoscopic ultrasound-guided entero-enterostomy (EUS EE) over enteroscopy-guided intervention, and the clinical outcomes of EUS EE. We expound on pre-procedural considerations, intra-procedural techniques and post-procedural care following EUS EE. We conclude that given the simplification of the technique and the ability to place a stent away from the tumor, EUS EE is a promising technique that will likely be established as the treatment of choice for ALS.
Subject(s)
Afferent Loop Syndrome , Humans , Afferent Loop Syndrome/diagnostic imaging , Afferent Loop Syndrome/etiology , Afferent Loop Syndrome/surgery , Endoscopy , Endosonography/methods , Stents , Ultrasonography, InterventionalABSTRACT
Afferent loop syndrome (ALS) is an uncommon complication of gastrojejunostomy. It may be acute or chronic depending on whether symptoms manifest within 7 days of surgery. Rarely acute ALS may give rise to acute pancreatitis. It may present early in the postoperative course and, if diagnosed late, may result in organ failure within 48h. We report a middle-aged woman with carcinoma of the stomach managed by subtotal gastrectomy with Billroth II gastrojejunostomy and Braun jejunojejunostomy. The patient developed vomiting and abdominal pain in the first postoperative day with acute renal shutdown and about 500ml drain output of dirty fluid. On investigation, a diagnosis of acute pancreatitis due to afferent loop syndrome was made, and the patient was resuscitated in the intensive care unit. However, she showed early signs of organ failure and succumbed to her condition within 6 days of surgery. Since the complication is rare following gastrojejunostomy and often mimics ALS, an early diagnosis becomes difficult. If delay in management happens, premature organ failure may lead to high morbidity and mortality.
Subject(s)
Afferent Loop Syndrome , Gastric Bypass , Pancreatitis , Stomach Neoplasms , Female , Humans , Middle Aged , Acute Disease , Afferent Loop Syndrome/diagnosis , Afferent Loop Syndrome/etiology , Afferent Loop Syndrome/surgery , Gastrectomy/adverse effects , Gastric Bypass/adverse effects , Pancreatitis/etiology , Pancreatitis/complications , Postoperative Period , Stomach Neoplasms/surgery , Stomach Neoplasms/complicationsABSTRACT
Afferent loop syndrome is a late adverse event after gastrojejunostomy which involves increased intraluminal pressure, progresses rapidly, and requires appropriate decompression treatment. Patients in poor condition require less invasive treatments. Yamamoto and colleagues report a case of successful treatment of malignant afferent loop syndrome with hemorrhage by endoscopic ultrasound-guided gastrojejunostomy.
Subject(s)
Afferent Loop Syndrome , Gastric Bypass , Afferent Loop Syndrome/diagnostic imaging , Afferent Loop Syndrome/etiology , Afferent Loop Syndrome/surgery , Endosonography , Gastric Bypass/adverse effects , Hemorrhage , Humans , Ultrasonography, InterventionalABSTRACT
OBJECTIVES: Where palliative surgery or percutaneous drainage used to be the only option in patients with afferent loop syndrome, endoscopic management by EUS-guided gastroenterostomy has been gaining ground. However, EUS-guided hepaticogastrostomy might also provide sufficient biliary drainage. Our aim was to evaluate the feasibility of EUS-guided hepaticogastrostomy for the management of afferent loop syndrome and provide comparative data on the different approaches. METHODS: The institutional databases were queried for all consecutive minimally invasive procedures for afferent loop syndrome. A retrospective, dual-centre analysis was performed, separately analysing EUS-guided hepaticogastrostomy, EUS-guided gastroenterostomy and percutaneous drainage. Efficacy, safety, need for re-intervention, hospital stay and overall survival were compared. RESULTS: In total, 17 patients were included (mean age 59 years (± SD 10.5), 23.5% female). Six patients, which were ineligible for EUS-guided gastroenterostomy, were treated with EUS-guided hepaticogastrostomy. EUS-guided gastroenterostomy and percutaneous drainage were performed in 6 and 5 patients respectively. Clinical success was achieved in all EUS-treated patients, versus 80% in the percutaneous drainage group (p = 0.455). Furthermore, higher rates of bilirubin decrease were seen among patients undergoing EUS: > 25% bilirubin decrease in 10 vs. 1 patient(s) in the percutaneously drained group (p = 0.028), with > 50% and > 75% decrease identified only in the EUS group. Using the ASGE lexicon for adverse event grading, adverse events occurred only in patients treated with percutaneous drainage (60%, p = 0.015). And last, the median number of re-interventions was significantly lower in patients undergoing EUS (0 (IQR 0.0-1.0) vs. 1 (0.5-2.5), p = 0.045) when compared to percutaneous drainage. CONCLUSIONS: In the management of afferent loop syndrome, EUS seems to outperform percutaneous drainage. Moreover, in our cohort, EUS-guided gastroenterostomy and hepaticogastrostomy provided similar outcomes, suggesting EUS-guided hepaticogastrostomy as the salvage procedure in situations where EUS-guided gastroenterostomy is not feasible or has failed.
Subject(s)
Afferent Loop Syndrome , Cholestasis , Afferent Loop Syndrome/etiology , Afferent Loop Syndrome/surgery , Bilirubin , Cholangiopancreatography, Endoscopic Retrograde , Cholestasis/etiology , Cholestasis/surgery , Drainage/methods , Endosonography/methods , Female , Gastroenterostomy , Humans , Male , Middle Aged , Retrospective Studies , StentsABSTRACT
Afferent loop syndrome (ALS) is a mechanical complication that arises after gastric surgery with gastrojejunostomy reconstruction. This condition was first described in 1950 by Roux, Pedoussaut, and Marchal to post-gastrectomy patients with bilious vomiting. Acute ALS is associated with complete obstruction and considered a surgical emergency, whereas chronic ALS is mostly related to partial obstruction of the afferent loop. The delay in diagnosis may lead to intestinal ischemia, perforation and can be associated with a high mortality rate up to 60%. Surgery is usually the mainstay treatment of ALS, but endoscopic therapy, including stent placement in malignancy-related, anastomotic stricture dilation, has been evolving over the past recent years.
Subject(s)
Afferent Loop Syndrome , Gastric Bypass , Afferent Loop Syndrome/diagnostic imaging , Afferent Loop Syndrome/etiology , Dilatation , Gastrectomy , HumansABSTRACT
Afferent loop syndrome is a rare complication after gastrectomy with Billroth II or Roux-en-Y reconstruction, caused by an obstruction in the proximal loop. The biliary stasis and bacterial overgrowth secondary to this obstruction can lead to repeated episodes of acute cholangitis. We present the case of a male patient who had previously undergone gastrectomy with Roux-en-Y reconstruction and later experienced multiple episodes of acute cholangitis secondary to choledocolithiasis. He underwent an open exploration of the bile ducts with choledocolitotomy, but the events of cholangitis persisted. Further investigation permitted to identify a dilation of the biliary loop of the Roux-en-Y anastomosis, suggesting enterobiliary reflux as the cause of recurrent acute cholangitis. Therefore, a bowel enterectomy and new jejunojejunostomy were undertaken, and normal biliary flow was re-established. The surgical treatment is mandatory in benign causes, leading to the resolution of the obstruction and subsequent normalisation of bile flow.